Articles related to Oncology, Medical

The Journal of Clinical Oncology has a heartfelt account of one family’s struggle to access medical records after the death of a child from a brain tumor. Closing down online access to medical records is a common practice at hospitals and healthcare clinics following the death of a patient, often to the pain of family members who still have questions and seek answers.

Clinical Advances in Hematology & Oncology talks with Sonali M. Smith, MD, an Elwood V. Jensen Professor in Medicine and Chief, Section of Hematology/Oncology at the University of Chicago, about all things transformed lymphoma, including risk factors, distinguishing characteristics, pathogenesis, traditional treatment approaches, treatment goals, new treatment strategies, and other promising areas of research.

The U.S. Food and Drug Administration (FDA) held a two-day public meeting to discuss managing the potential side effects of gene therapies following the death of a boy with a rare neuromuscular disease. High doses of gene therapies are known to cause liver damage, and recent studies have also found a potential long-term cancer risk in mice and dogs treated with gene therapies.

You want speedy access to comprehensive records. Clinical decision-making tools. Optimized communication and data exchange. EHRs should be as unique as you, so whether you’re looking to replace or implement your first, this list can get you started.

Although the 2020 numbers will likely look MUCH different, the Merritt Hawkins survey from 2019 showed increased gains from previous years. Of the 62 responses representing 93 hospitals, cardiovascular surgery drove the most revenue. Still, the outlook remains bleak post-pandemic.

The updated NCCN guidelines no longer say that active surveillance is “preferred” for low-risk prostate cancer, prompting some physicians to claim this recommendation may encourage overtreatment and is a “step back” from progress made over the last decade, which has been defined by active surveillance as the preferable care option for most low-risk localized prostate cancer patients.